These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25856652)

  • 1. Temporal macular dimple in retinopathy of prematurity.
    Behera UC; Tripathy D; Singh J
    JAMA Ophthalmol; 2015 Apr; 133(4):e145348. PubMed ID: 25856652
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
    Park SW; Jung HH; Heo H
    Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
    [No Abstract]   [Full Text] [Related]  

  • 3. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab (avastin) for the treatment of retinopathy of prematurity.
    Beaulieu MJ
    Neonatal Netw; 2012; 31(4):242-7. PubMed ID: 22763251
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
    Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
    Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
    [No Abstract]   [Full Text] [Related]  

  • 9. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
    Goldman DR; Baumal CR
    J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 14. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 17. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
    Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
    Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
    Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
    Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
    [No Abstract]   [Full Text] [Related]  

  • 20. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
    Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
    J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.